Clinical and experimental studies have shown increased concentrations of TNF-a and its soluble receptors in serum of patients with acute pancreatitis. In this work, we have investigated the time-course of TNF-a and its soluble receptors during taurocholateinduced acute pancreatitis. In addition, since TNF-a itself could mediate the shedding of its receptors, we have assessed the effect of inhibiting TNF-a production on the release of soluble TNF-a receptors in experimental acute pancreatitis. Our results indicate that soluble receptors are released in the early stages of the disease and this increase is concomitant with the release of TNF-a, which is mainly bound to specific proteins. The increased concentrations of its receptors strongly suggest that they could be these binding proteins. Inhibition of TNF-a generation with pentoxifylline abrogated the shedding of sTNF-aR1, but had no effect on sTNF-aR2. This finding suggests that the shedding of sTNF-aR1 is induced by TNF-a itself, but in the case of sTNF-aR2, the shedding appears to be induced by another mechanism.
Introduction
Acute pancreatitis is a systemic disease with a variable prognosis depending not only on the local conditions, but also on systemic manifestations, in particular lung injury [1] . The mechanism responsible for the involvement of distant organs is still unclear and different pathways have been suggested, including activated complement [2] , oxygen-derived free radicals [3] and cytokines, in particular TNF-a and IL-1b [4] .
TNF-a is a cytokine produced in response to numerous stimuli and induces acute inflammation by enhancing endothelial permeability, inflammatory cell recruitment and release of superoxide anion and additional cytokines by polymorphonuclear leukocytes. Nucleated cells contain two TNF-a receptors with molecular weights of 55e60 (TNF-aR1) and 75e80 (TNF-aR2) kDa, respectively [5] . Under inflammatory stimuli, the extracellular part of both receptors is shed by proteolytic cleavage and circulates as a soluble receptor (sTNF-aR) that binds to free TNF-a in plasma [6] .
Clinical and experimental studies have shown increased concentrations of TNF-a and its soluble receptors in serum of patients with acute pancreatitis that appear to correlate with the severity of the disease [7] . In addition, when circulating TNF-a is blocked or the production of TNF-a prevented, the severity of pancreatitis and its systemic effects are reduced [8, 9] . Furthermore, studies using knockout animals have demonstrated that cytokine receptors are required for the development of systemic inflammation during acute pancreatitis [10] .
The aim of this work was to evaluate the time-course of TNF-a and its soluble receptors during an experimental model of acute pancreatitis. In addition, since TNF-a itself could mediate the shedding of its receptors, we have investigated the effect of inhibiting TNF-a production on the release of soluble TNF-a receptors in experimental acute pancreatitis.
Methods

Animals and pancreatitis model
Male Wistar rats (250e300 g bw) were anesthetized with an i.p. administration of ketamine (80 mg/kg bw) and acepromacine (2.5 mg/kg bw). Pancreatitis was induced by retrograde injection of 0.1 ml/100 g bw sodium taurocholate (3.5%) (Sigma, St Louis, Missouri, USA) into the biliopancreatic duct [11] .
Experimental design
In a first series of experiments, the time-course of free and total TNF-a were performed, by measuring samples obtained at 1, 3, 6 and 9 h after induction of pancreatitis (n ¼ 6 for each group). Control samples were considered as those obtained immediately after pancreatitis induction (t ¼ 0).
In a second series of experiments, TNF-a production was avoided by intravenous administration of pentoxifylline (Laboratorios Robert, Barcelona, Spain). In this series, control animals received an intraductal infusion of saline solution (NaCl 0.9%) (n ¼ 6 for each group). Serum and lung tissue samples were obtained 6 h after induction.
Lipase assay
Serum lipase was determined by using a commercial kit from Roche (Mannheim, Germany), according to the supplier's specifications.
Myeloperoxidase assay
Myeloperoxidase was measured employing 3,3#,5,5#-tetramethylbenzidine as a substrate [12] . Enzyme activity was assessed photometrically at 630 nm. An enzyme unit is defined as the amount of enzyme that produces an increase of 1 absorbance unit per minute.
TNF-a
To determine the levels of TNF-a in serum, two different commercial kits were used: free TNF-a was measured by a commercial solid phase sandwich enzyme linked immuno-sorbent assay (ELISA) from Biosource International (Camarillo, California, USA) and total (bound and free) TNF-a by a competitive enzyme-immunoassay kit from Chemicon International (Temecula, CA, USA). A common TNF-a standard was used to calibrate the response of the different kits at high and low levels of the standard curve and variation was !10%.
sTNF-aR1 and sTNF-aR2
To measure the levels of circulating TNF-a soluble receptors -1 and -2, commercial solid phase ELISA from R&D Systems (Minneapolis, USA) were employed. To discard possible interferences due to the presence of TNF-a in the measure of its soluble receptors, assay kits were validated by measuring the effect of adding different concentrations of TNF-a (rat TNF-a, PedroTech, Inc. Rocky Hills, NJ; Ref to the standard soluble receptor solution.
Results
Total TNF-a levels in serum increased significantly 1 h after induction of pancreatitis and remained increased up to 9 h post-induction (Fig. 1) . By contrast, free TNF-a levels showed a transient increase within the first hour and low levels when compared to the total TNF-a.
Both sTNF-aR1 and sTNF-aR2 showed increased levels in plasma 1 h after pancreatitis induction and remained increased during the course of the experiment (Fig. 2) . Levels of sTNF-aR2 were three-fold higher than those of sTNF-aR1.
The presence of increased concentrations of TNF-a does not affect the performance of the immunoassays since measures obtained after overloading with two different concentrations of TNF-a does not differ from the expected values (Table 1) .
The effect of pentoxifylline has been evaluated 6 h after pancreatitis induction. This treatment completely inhibited the plasma total TNF-a increase. It had no significant effect on lipase activity and only a moderate effect reducing the neutrophil infiltration into the lungs (Fig. 3) . Concerning the release of soluble receptors, pentoxifylline treatment abolished the increase observed in sTNF-aR1 levels, but had no effect on sTNF-aR2 levels (Fig. 4) .
Discussion
Cytokines, particularly TNF-a, are suspected to play a central role orchestrating the inflammatory response in the early stages of acute pancreatitis [4] , but TNF-a is often undetectable in patients even with severe disease. This lack of detection could be related to high levels of soluble forms of its receptors present in plasma that could bind circulating TNF-a and interfering with its detection.
Our results indicate that soluble receptors are released in the early stages of the disease and this increase is concomitant with the release of TNF-a. By using two different assays that discriminate between the free form of TNF-a and that bound to proteins we observed that TNF-a is mainly present bound to specific proteins. The increased concentrations of its receptors strongly suggest that they could be these binding proteins. Only Fig. 1 . Total (upper) TNF-a levels in serum remained significantly increased during all the time periods evaluated. In contrast, free TNF-a (lower) showed very low levels (at the range of pg/ml) and only a transient increase could be observed at the first hour. * = p ! 0:05 vs time = 0. Fig. 2 . sTNF-aR1 and sTNF-aR2 levels after induction of pancreatitis. Both soluble receptors increased its concentration in serum 1 h after pancreatitis induction and remained increased during the course of the experiment. Note that concentration of sTNF-aR2 is three-fold greater than sTNF-aR1. * = p ! 0:05 vs time = 0. Table 1 Measurements of sTNF-aR1 and sTNF-aR2 after overloading standards with different amounts of TNF-a TNF-a added (ng/ml) sTNF-aR1 expected (pg/ml) sTNF-aR1 found (pg/ml) sTNF-aR1 (%) sTNF-aR2 expected (pg/ml) sTNF-aR2 found (pg/ml) sTNF-aR2 (%)   0   125  130  104  125  138  110  250  272  109  250  287  115  500  557  111  500  547  110   1   125  120  96  125  134  107  250  232  93  250  269  108  500  470  94  500  470  94   10   125  123  99  125  156  125  250  243  97  250  274  110  500  497  99  500  517  103 The presence of the cytokine does not interfere with the measurement of its receptors.
a transient increase in the free form of TNF-a in the initial stages of the disease could be observed. The release of soluble receptors could be a protective mechanism against excessive TNF-a activity. Proteolytic cleavage (shedding) is a well-documented mechanism to down-regulate the cell response to TNF-a. Less clear is the physiological role of circulating soluble receptors. It has been suggested that they act by buffering the effect of TNF-a by blocking the protein and preventing its binding to cell receptors [13] . On the other hand, TNF-a half-life in plasma is relatively short due to the trimeric structure of TNF-a and binding to soluble receptors stabilizes its structure increasing half-life [14] . Both possibilities are not mutually exclusive. Soluble receptors could modulate the effect of TNF-a at the site of synthesis and facilitate TNF-a transport to distant organs promoting its systemic effects. Nevertheless, it has been reported that the neutralizing capacity of sTNF-aR is relatively low and a 30-to 300-fold molar excess of sTNF-aR are required to inhibit the cytotoxic action of TNF-a [13] . The fact that we have found similar levels of TNF-a and its receptors could suggest a role stabilizing the trimeric structure of TNF-a more than buffering the effects of this cytokine. Of course, the effect of other non-specific binding-proteins could not be excluded. On the other hand, underestimation of sTNF-aR due to a possible interference of TNF-a present in the samples was discarded by measuring standards overloaded with TNF-a ( Table 1) .
Different stimuli, including TNF-a itself, enhance the release of sTNF-aR into the circulation [6] . It is noteworthy that, during acute pancreatitis, inhibition of TNF-a generation with pentoxifylline abrogated the shedding of sTNF-aR1 but had no effect on sTNF-aR2 (Fig. 4) . Previous works focused on the mechanism of Fig. 3 . Effect of pentoxifylline treatment in lipase activity (upper), lung myeloperoxidase activity (middle) and total TNF-a (lower) levels, 6 h after induction of pancreatitis. Pentoxifylline inhibits the production of TNF-a, partially reduced the inflammatory process in the lung, and has no effect on pancreatic damage. * = p ! 0:05 vs control; C = p ! 0:05 vs pancreatitis. Fig. 4 . Effect of pentoxifylline (Ptx) treatment on the release of soluble receptors 6 h after induction of pancreatitis. Inhibition of TNF-a production prevents the release of sTNF-aR1, but has no effect on sTNF-aR2. * = p ! 0:05 vs control; C = p ! 0:05 vs pancreatitis.
shedding of TNF-a receptors demonstrated differences between sTNF-aR1 and TNF-aR2. It has been reported that down-regulation of its receptors by TNF-a is due to the shedding of sTNF-aR75 and the internalization and shedding of sTNF-aR55. In this regard, our results suggest the involvement of a TNF-a-depending mechanism for sTNF-aR1 and a different mechanism, nondirectly related with TNF-a for TNF-aR2. In fact, pancreatitis is characterized by the simultaneous activation of different pro-inflammatory pathways, including free radical generation, cytokine synthesis and complement system activation [2e4]. In addition, damaged pancreatic cells release proteolytic enzymes. Some of these mechanisms could act inducing the shedding of TNF-a receptors.
In conclusion, our results indicate that during early stages of pancreatitis, TNF-a and its soluble receptors are released to systemic circulation and maintained at a high concentration. The shedding of sTNF-aR1 seems to be induced by TNF-a itself, but in the case of sTNF-aR2, the shedding appears to be induced by another mechanism. In plasma, TNF-a is present bound to its soluble receptors, but the precise role of this binding remains to be elucidated.
